Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 256

1.

Prospective phase II trial of neoadjuvant chemotherapy with gemcitabine and cisplatin for resectable adenocarcinoma of the pancreatic head.

Heinrich S, Pestalozzi BC, Schäfer M, Weber A, Bauerfeind P, Knuth A, Clavien PA.

J Clin Oncol. 2008 May 20;26(15):2526-31. doi: 10.1200/JCO.2007.15.5556.

2.

Neoadjuvant chemotherapy generates a significant tumor response in resectable pancreatic cancer without increasing morbidity: results of a prospective phase II trial.

Heinrich S, Schäfer M, Weber A, Hany TF, Bhure U, Pestalozzi BC, Clavien PA.

Ann Surg. 2008 Dec;248(6):1014-22. doi: 10.1097/SLA.0b013e318190a6da.

PMID:
19092346
3.

Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study).

Heinrich S, Pestalozzi B, Lesurtel M, Berrevoet F, Laurent S, Delpero JR, Raoul JL, Bachellier P, Dufour P, Moehler M, Weber A, Lang H, Rogiers X, Clavien PA.

BMC Cancer. 2011 Aug 10;11:346. doi: 10.1186/1471-2407-11-346.

4.

NeoGemOx: Gemcitabine and oxaliplatin as neoadjuvant treatment for locally advanced, nonmetastasized pancreatic cancer.

Sahora K, Kuehrer I, Eisenhut A, Akan B, Koellblinger C, Goetzinger P, Teleky B, Jakesz R, Peck-Radosavljevic M, Ba'ssalamah A, Zielinski C, Gnant M.

Surgery. 2011 Mar;149(3):311-20. doi: 10.1016/j.surg.2010.07.048. Epub 2010 Sep 6.

PMID:
20817204
5.

NeoGemTax: gemcitabine and docetaxel as neoadjuvant treatment for locally advanced nonmetastasized pancreatic cancer.

Sahora K, Kuehrer I, Schindl M, Koelblinger C, Goetzinger P, Gnant M.

World J Surg. 2011 Jul;35(7):1580-9. doi: 10.1007/s00268-011-1113-8.

PMID:
21523499
6.

Neoadjuvant chemotherapy with gemcitabine and S-1 for resectable and borderline pancreatic ductal adenocarcinoma: results from a prospective multi-institutional phase 2 trial.

Motoi F, Ishida K, Fujishima F, Ottomo S, Oikawa M, Okada T, Shimamura H, Takemura S, Ono F, Akada M, Nakagawa K, Katayose Y, Egawa S, Unno M.

Ann Surg Oncol. 2013 Nov;20(12):3794-801. doi: 10.1245/s10434-013-3129-9. Epub 2013 Jul 10.

PMID:
23838925
7.

Adjuvant PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) or gemcitabine followed by chemoradiation in pancreatic cancer: a randomized phase II trial.

Reni M, Balzano G, Aprile G, Cereda S, Passoni P, Zerbi A, Tronconi MC, Milandri C, Saletti P, Rognone A, Fugazza C, Magli A, Di Muzio N, Di Carlo V, Villa E.

Ann Surg Oncol. 2012 Jul;19(7):2256-63. doi: 10.1245/s10434-011-2205-2. Epub 2012 Jan 12.

PMID:
22237835
8.

Neoadjuvant/preoperative gemcitabine for patients with localized pancreatic cancer: a meta-analysis of prospective studies.

Andriulli A, Festa V, Botteri E, Valvano MR, Koch M, Bassi C, Maisonneuve P, Sebastiano PD.

Ann Surg Oncol. 2012 May;19(5):1644-62. doi: 10.1245/s10434-011-2110-8. Epub 2011 Oct 20. Review.

PMID:
22012027
9.

Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer: results of the first prospective randomized phase II trial.

Golcher H, Brunner TB, Witzigmann H, Marti L, Bechstein WO, Bruns C, Jungnickel H, Schreiber S, Grabenbauer GG, Meyer T, Merkel S, Fietkau R, Hohenberger W.

Strahlenther Onkol. 2015 Jan;191(1):7-16. doi: 10.1007/s00066-014-0737-7. Epub 2014 Sep 25.

10.

Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival.

Rose JB, Rocha FG, Alseidi A, Biehl T, Moonka R, Ryan JA, Lin B, Picozzi V, Helton S.

Ann Surg Oncol. 2014 May;21(5):1530-7. doi: 10.1245/s10434-014-3486-z. Epub 2014 Jan 29. Erratum in: Ann Surg Oncol. 2014 May;21(5):1538. Dosage error in article text.

PMID:
24473642
11.

Long-term follow-up of a pilot phase II study with neoadjuvant epidoxorubicin, etoposide and cisplatin in gastric cancer.

Barone C, Cassano A, Pozzo C, D'Ugo D, Schinzari G, Persiani R, Basso M, Brunetti IM, Longo R, Picciocchi A.

Oncology. 2004;67(1):48-53.

PMID:
15459495
12.

Successful adjuvant bi-weekly gemcitabine chemotherapy for pancreatic cancer without impairing patients' quality of life.

Toyama Y, Yoshida S, Saito R, Kitamura H, Okui N, Miyake R, Ito R, Son K, Usuba T, Nojiri T, Yanaga K.

World J Surg Oncol. 2013 Jan 9;11:3. doi: 10.1186/1477-7819-11-3.

13.

Induction gemcitabine and oxaliplatin therapy followed by a twice-weekly infusion of gemcitabine and concurrent external-beam radiation for neoadjuvant treatment of locally advanced pancreatic cancer: a single institutional experience.

Leone F, Gatti M, Massucco P, Colombi F, Sperti E, Campanella D, Regge D, Gabriele P, Capussotti L, Aglietta M.

Cancer. 2013 Jan 15;119(2):277-84. doi: 10.1002/cncr.27736. Epub 2012 Jul 6.

14.

A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: gemcitabine alone versus gemcitabine combined with cisplatin.

Palmer DH, Stocken DD, Hewitt H, Markham CE, Hassan AB, Johnson PJ, Buckels JA, Bramhall SR.

Ann Surg Oncol. 2007 Jul;14(7):2088-96. Epub 2007 Apr 24.

PMID:
17453298
15.

Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head.

Varadhachary GR, Wolff RA, Crane CH, Sun CC, Lee JE, Pisters PW, Vauthey JN, Abdalla E, Wang H, Staerkel GA, Lee JH, Ross WA, Tamm EP, Bhosale PR, Krishnan S, Das P, Ho L, Xiong H, Abbruzzese JL, Evans DB.

J Clin Oncol. 2008 Jul 20;26(21):3487-95. doi: 10.1200/JCO.2007.15.8642.

16.

Locally advanced esophageal adenocarcinoma: response to neoadjuvant chemotherapy and survival predicted by ([18F])FDG-PET/CT.

Kauppi JT, Oksala N, Salo JA, Helin H, Karhumäki L, Kemppainen J, Sihvo EI, Räsänen JV.

Acta Oncol. 2012 May;51(5):636-44. doi: 10.3109/0284186X.2011.643822. Epub 2012 Jan 2.

PMID:
22208782
17.

Histopathological response to preoperative chemoradiation for resectable pancreatic adenocarcinoma: the French Phase II FFCD 9704-SFRO Trial.

Le Scodan R, Mornex F, Partensky C, Mercier C, Valette PJ, Ychou M, Roy P, Scoazec JY.

Am J Clin Oncol. 2008 Dec;31(6):545-52. doi: 10.1097/COC.0b013e318172d5c5.

PMID:
19060585
18.

Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas.

Ko AH, Dito E, Schillinger B, Venook AP, Bergsland EK, Tempero MA.

J Clin Oncol. 2006 Jan 20;24(3):379-85. Epub 2005 Dec 12.

19.

A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer.

Kim EJ, Ben-Josef E, Herman JM, Bekaii-Saab T, Dawson LA, Griffith KA, Francis IR, Greenson JK, Simeone DM, Lawrence TS, Laheru D, Wolfgang CL, Williams T, Bloomston M, Moore MJ, Wei A, Zalupski MM.

Cancer. 2013 Aug 1;119(15):2692-700. doi: 10.1002/cncr.28117. Epub 2013 May 29.

20.
Items per page

Supplemental Content

Write to the Help Desk